Analyst Price Targets — AMLX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 27, 2026 10:55 am | Seamus Fernandez | Guggenheim | $57.00 | $37.08 | StreetInsider | Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $57 at Guggenheim |
| August 19, 2026 11:23 am | — | Guggenheim | $55.00 | $35.11 | TheFly | Amylyx price target raised to $55 from $40 at Guggenheim |
| August 18, 2026 7:40 pm | Graig Suvannavejh | Mizuho Securities | $42.00 | $35.11 | StreetInsider | Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $42 at Mizuho |
| August 18, 2026 7:01 pm | — | Robert W. Baird | $52.00 | $35.11 | TheFly | Amylyx price target raised to $52 from $28 at Baird |
| August 18, 2026 4:28 pm | Andrew Fein | H.C. Wainwright | $55.00 | $35.11 | StreetInsider | Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $55 at H.C. Wainwright |
| August 18, 2026 4:18 pm | — | UBS | $55.00 | $33.32 | TheFly | Amylyx price target raised to $55 from $34 at H.C. Wainwright |
| August 18, 2026 3:19 pm | — | UBS | $45.00 | $33.09 | TheFly | Amylyx price target raised to $45 from $21 at Stifel |
| August 17, 2026 10:46 am | Graig Suvannavejh | Mizuho Securities | $30.00 | $21.63 | TheFly | Amylyx price target raised to $30 from $24 at Mizuho |
| August 7, 2026 11:50 am | — | Robert W. Baird | $28.00 | $24.19 | TheFly | Amylyx price target raised to $28 from $19 at Baird |
| July 20, 2026 10:31 am | Graig Suvannavejh | Mizuho Securities | $24.00 | $17.75 | StreetInsider | Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $24 at Mizuho |
Latest News for AMLX
Amylyx Pharmaceuticals raised $500 million to strengthen its balance sheet. A potential 2027 drug launch could provide the company's next catalyst.
BlackRock Inc. bought a new position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 8,827,085 shares of the company's stock, valued at approximately $158,534,000. BlackRock Inc. owned approximately 7.94% of Amylyx Pharmaceuticals as
BlackRock Inc. bought a new position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 8,827,085 shares of the company's stock, valued at approximately $158,534,000. BlackRock Inc. owned approximately 7.94% of Amylyx Pharmaceuticals as
Certain stocks are such poor bets that they are likely to lose ground even in bull markets.
Almitas Capital LLC acquired a new stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 974,881 shares of the company's stock, valued at approximately $17,509,000. Amylyx Pharmaceuticals comprises approximately 4.2% of Almitas
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AMLX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.